| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/31/2000 | EP1003729A1 6-azauracil derivatives as il-5 inhibitors |
| 05/31/2000 | EP1003728A1 2- 3- 4-(2-t-butyl-6- trifluoromethylpyridin-4-yl) piperazin-1-yl] propylmercapto pyrimidin-4-ol-fumarate |
| 05/31/2000 | EP1003724A1 Substituted quinoline derivatives with antiviral action |
| 05/31/2000 | EP1003723A1 2-acylaminopropanamines as tachykinin receptor antagonists |
| 05/31/2000 | EP1003722A1 Crystalline 10,10-bis((2-fluoro-4-pyridinyl)methyl)-9(10h)-anthracenone and an improved process for preparing the same |
| 05/31/2000 | EP1003721A1 Benzylidene-1,3-dihydro-indol-2-one derivatives as receptor tyrosine kinase inhibitors, particularly of raf kinases |
| 05/31/2000 | EP1003720A1 Aryloxyarylsulfonylamino hydroxamic acid derivatives |
| 05/31/2000 | EP1003713A1 Anthranilic acid analogs |
| 05/31/2000 | EP1003712A1 Anthranilic acid analogs |
| 05/31/2000 | EP1003706A1 Cyclohexenone long-chain alcohol and medicament containing same |
| 05/31/2000 | EP1003569A2 Sterile bioerodible implant device with improved biocompatability and method |
| 05/31/2000 | EP1003568A1 Hemostatic tissue sealants |
| 05/31/2000 | EP1003559A2 Immobilization of vitamin a acid by cationic polyelectrolytes |
| 05/31/2000 | EP1003558A1 Lipid-polyamide conjugates and compositions for nucleic acid delivery |
| 05/31/2000 | EP1003557A2 New salts with beneficial organoleptic properties |
| 05/31/2000 | EP1003555A1 Controlled release of ophthalmic compositions |
| 05/31/2000 | EP1003554A1 Proton pump inhibitor in therapeutic combination with antibacterial substances |
| 05/31/2000 | EP1003553A1 The use of angiostatic steroids in photodynamic therapy |
| 05/31/2000 | EP1003542A1 Use of substances having oxytocin activity for preparation of medicaments for wound healing |
| 05/31/2000 | EP1003541A1 Inhibitors of hiv reverse transcriptase |
| 05/31/2000 | EP1003540A1 $g(b)2-ADRENERGIC RECEPTOR AGONISTS |
| 05/31/2000 | EP1003532A1 Absorption of minerals by intestinal cells |
| 05/31/2000 | EP1003530A1 Eye treatments using synthetic thyroid hormone compositions |
| 05/31/2000 | EP1003529A1 Method for promoting weight and fat loss with a composition comprising hydroxycitrate, carnitine and a pyruvate promotor |
| 05/31/2000 | EP1003528A1 Method of enhancing bioavailability of fexofenadine and its derivatives |
| 05/31/2000 | EP1003527A1 Polynucleotide compositions |
| 05/31/2000 | EP1003526A1 Covalently linked n,o-carboxymethylchitosan and uses thereof |
| 05/31/2000 | EP1003525A1 Composition and method for regulating cell proliferation and cell death |
| 05/31/2000 | EP1003524A1 New formulation |
| 05/31/2000 | EP1003523A1 Method of treatment of liver tumours and pharmaceutical compositions for use therein |
| 05/31/2000 | EP1003522A1 A method for preventing or controlling cataract |
| 05/31/2000 | EP1003521A1 Methods to potentiate intravenous estramustine phosphate |
| 05/31/2000 | EP1003520A1 Method and composition for treatment of erectile dysfunction |
| 05/31/2000 | EP1003519A1 Supression of cyclin kinase 2 activity for prevention and treatment of dna viral infections |
| 05/31/2000 | EP1003518A1 A method for the treatment of mental illness in mammals and a composition therefor |
| 05/31/2000 | EP1003517A1 Pharmaceutical composition for the treatment of so-called restless legs |
| 05/31/2000 | EP1003516A1 Methods of administering camptothecin compounds for the treatment of cancer with reduced side effects |
| 05/31/2000 | EP1003515A1 Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia |
| 05/31/2000 | EP1003514A1 Cyclic amine modulators of chemokine receptor activity |
| 05/31/2000 | EP1003513A1 Medicinal product and method for treatment and prevention of cognitive disorders |
| 05/31/2000 | EP1003512A1 ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS |
| 05/31/2000 | EP1003511A1 ALPHA 1aADRENERGIC RECEPTOR ANTAGONISTS |
| 05/31/2000 | EP1003510A1 Method for treating headache pain with topical local anesthetic compositions |
| 05/31/2000 | EP1003509A1 Il-8 receptor antagonists |
| 05/31/2000 | EP1003508A1 Antimutagenic agents |
| 05/31/2000 | EP1003507A1 Combination therapy comprising amlodipine and a statin compound |
| 05/31/2000 | EP1003506A1 Method of treating isolated systolic hypertension |
| 05/31/2000 | EP1003505A1 Heterocyclic vinylethers against neurological disorders |
| 05/31/2000 | EP1003504A2 Indole derivatives and their use as mcp-1 antagonists |
| 05/31/2000 | EP1003503A1 Therapeutic combinations comprising amlodipin and atorvastatin |
| 05/31/2000 | EP1003502A1 Enantiomers of 4- (cyanoimino)- (1,2,2-trimethylpropyl) amino]methyl]amino] benzonitrile |
| 05/31/2000 | EP1003501A1 Means of ascertaining an individual's risk profile for atherosclerotic disease |
| 05/31/2000 | EP1003500A1 Intramural delivery of nitric oxide enhancer for inhibiting lesion formation after vascular injury |
| 05/31/2000 | EP1003499A1 Diclofenac solution for topical application |
| 05/31/2000 | EP1003498A1 Di-aryl ethers and their derivatives as anti-cancer agents |
| 05/31/2000 | EP1003497A1 Il-8 receptor antagonists |
| 05/31/2000 | EP1003496A1 Method for chemoprevention of prostate cancer |
| 05/31/2000 | EP1003495A1 Pharmaceutical compounds |
| 05/31/2000 | EP1003494A1 (d)-METHADONE, A NONOPIOID ANALGESIC |
| 05/31/2000 | EP1003493A1 Use of selective rxr agonists to prevent surgical adhesions |
| 05/31/2000 | EP1003492A2 Inhibitors of nf-kappab as activators of hsf and inducers of heat shock proteins |
| 05/31/2000 | EP1003491A1 Use of antagonists or partial agonists of the vanilloid receptor complexes for treating neurodegenerative diseases |
| 05/31/2000 | EP1003490A1 Transdermal therapeutic system (tts) for administering sexual steroid hormones |
| 05/31/2000 | EP1003489A1 Film-forming compositions of antihyperalgesic opiates and method of treating hyperalgesic and pruritic conditions therewith |
| 05/31/2000 | EP1003488A1 Method for preparing vesicular nanocapsules |
| 05/31/2000 | EP1003487A1 Novel pharmaceutical formulation with controlled release of active substances |
| 05/31/2000 | EP1003486A2 Pharmaceutical compositions containing an effervescent acid-base couple |
| 05/31/2000 | EP1003484A1 Improved multiparticulate tablet with quick disintegration |
| 05/31/2000 | EP1003483A1 Tannic acid-polymer compositions for controlled release of pharmaceutical agents, particularly in the oral cavity |
| 05/31/2000 | EP1003480A1 Conjugated peptide nucleic acids having enhanced cellular uptake |
| 05/31/2000 | EP1003479A1 Method and compositions for treating late phase allergic reactions and inflammatory diseases |
| 05/31/2000 | EP1003478A1 Aqueous aerosol preparations containing biologically active macromolecules and method for producing the corresponding aerosols |
| 05/31/2000 | EP1003477A2 Therapeutical system for transdermal delivery of levonorgestrel |
| 05/31/2000 | EP1003476A1 Prolonged release active agent dosage form adapted for gastric retention |
| 05/31/2000 | EP1003474A1 Method of treating dry eye disease with purinergic receptor agonists |
| 05/31/2000 | EP1003473A1 Composition and method for treatment of aging skin |
| 05/31/2000 | EP1003465A1 Prevention/retardation of hair growth |
| 05/31/2000 | EP1003374A4 Inhibitors of farnesyl-protein transferase |
| 05/31/2000 | EP1003374A1 Inhibitors of farnesyl-protein transferase |
| 05/31/2000 | EP1003373A1 Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds |
| 05/31/2000 | EP1003370A1 Method of enhancing magnesium absorption and prevention of atherosclerosis |
| 05/31/2000 | EP0882016B1 Alkylated styrenes as prodrugs to cox-2 inhibitors |
| 05/31/2000 | EP0868181B1 Use of alpha,alpha-diphenylacetic acid-4-(n-methyl-piperidyl)ester as anti-spasmodic |
| 05/31/2000 | EP0865428B1 Vitamin d analogues |
| 05/31/2000 | EP0862551B1 Fluoro-substituted benzoylpropionic acid derivatives |
| 05/31/2000 | EP0820448B1 Novel taxoids, preparation thereof, and pharmaceutical compositions containing same |
| 05/31/2000 | EP0794942B1 Substituted biphenyl compounds for the treatment of inflammation |
| 05/31/2000 | EP0793495B1 Freeze-dried ondansetron compositions |
| 05/31/2000 | EP0747033B1 Transfusion liquid-containing holder and prepared transfusion liquid |
| 05/31/2000 | EP0721459B1 Novel oligosaccharide-containing 14-aminosteroid compounds and novel diastereoselective aminosteroid process chemistry |
| 05/31/2000 | EP0689440B1 Use of triazine compounds as anxiolytics |
| 05/31/2000 | EP0688215B1 3,4-diarylchromans for treatment of dermatitis |
| 05/31/2000 | EP0646005B1 Use of an imidazole for the preparation of a medicament for the treatment of arteriosclerosis |
| 05/31/2000 | EP0633775B1 Compounds useful for treating inflammatory diseases and for inhibiting production of tumor necrosis factor |
| 05/31/2000 | EP0627921B1 Method of inhibiting carcinogenesis by treatment with dehydroepiandrosterone and analogs thereof |
| 05/31/2000 | DE19955794A1 Pyrrolidin-Derivate-CCR-3-Rezeptor-Antagonisten Pyrrolidine derivatives-CCR-3 receptor antagonists |
| 05/31/2000 | DE19955340A1 CCR-3-Rezeptor-Antagonisten CCR-3 receptor antagonists |
| 05/31/2000 | DE19856475A1 Nichtsteroidale Entzündungshemmer Nonsteroidal anti-inflammatory drugs |
| 05/31/2000 | DE19854403A1 Phosphororganische Verbindungen und ihre Verwendung Organophosphorus compounds and their use |
| 05/31/2000 | DE19854402A1 Verwendung von Phosphonameisensäurederivaten zur therapeutischen und prophylaktischen Behandlung von Infektionen Using Phosphonameisensäurederivaten for the therapeutic and prophylactic treatment of infections |